Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > It's on Twitter... ASCO Results

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 04, 2023 11:35am

177 Views

Post# 35479139

RE:RE:RE:RE:It's on Twitter... ASCO Results

A second trial demonstrating that pelareorep works as a single agent is NEW PROOF that pelareorep works as an active anti-cancer agent and is able to convert an immunosuppressive TME to one that is more favorable to various I/O therapies including more effective ICI, CAR-T therapy, bispecifics, ADCs, and small molecules such as PARP and CDK4/6 inhibitors.

A PFS of 86% prepares pelareorep for an accelerated approval upon the filing of a Phase 3 registration study.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China